Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Hematopoietic cell transplantation in sickle cell disease

Shakila Khan, MD
Griffin P Rodgers, MD
Section Editor
Donald H Mahoney, Jr, MD
Deputy Editor
Jennifer S Tirnauer, MD


Hematopoietic cell transplantation (HCT) is an accepted form of treatment for some non-malignant hematologic disorders, such as aplastic anemia and beta thalassemia major. The use of HCT in sickle cell disease (SCD) is evolving. This topic review discusses the use of HCT in SCD. Other therapies for SCD including hydroxyurea and chronic blood transfusion therapy, and an overview of SCD management, are presented separately. (See "Hydroxyurea and other disease-modifying therapies in sickle cell disease" and "Red blood cell transfusion in sickle cell disease" and "Overview of the management and prognosis of sickle cell disease".)

The term HCT will be used throughout this review to refer to transplantation of stem and progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). In specific discussions related to the source of stem cells, the source will be specified (eg, peripheral blood stem cells).


HCT is a potentially curative treatment for hemoglobinopathies [1,2]. The most extensive experience showing the durable nature of cure has been established in patients with beta thalassemia major for more than a decade. In beta thalassemia major, the course of diminished life expectancy is fairly uniform; criteria for patient selection have, therefore, centered on the availability of a HLA-matched family donor and transplanting the patient early, before severe organ damage has occurred, in order to achieve a better outcome. (See "Efficacy of hematopoietic cell transplantation in beta thalassemia major".)

In the case of SCD, data concerning the efficacy of HCT are not as extensive, due in part to the following factors:

The clinical course of the disease is quite variable, and prognostic factors that might indicate which patients are most likely to develop advanced stage disease, and thus be candidates for HCT, are lacking.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 29, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Johnson FL, Look AT, Gockerman J, et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984; 311:780.
  2. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 2011; 118:1197.
  3. Kang EM, Areman EM, David-Ocampo V, et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002; 99:850.
  4. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012; 18:1265.
  5. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease. The European experience. Am J Pediatr Hematol Oncol 1994; 16:18.
  6. Bernaudin F, Souillet G, Vannier JP, et al. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO. Bone Marrow Transplant 1993; 12 Suppl 1:118.
  7. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335:369.
  8. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95:1918.
  9. Vermylen C, Cornu G. Hematopoietic stem cell transplantation for sickle cell anemia. Curr Opin Hematol 1997; 4:377.
  10. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126:896.
  11. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137:479.
  12. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110:2749.
  13. Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010; 16:263.
  14. McPherson ME, Hutcherson D, Olson E, et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011; 46:27.
  15. Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000; 26:1089.
  16. Kuentz M, Robin M, Dhedin N, et al. Is there still a place for myeloablative regimen to transplant young adults with sickle cell disease? Blood 2011; 118:4491.
  17. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014; 312:48.
  18. Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 2014; 99:811.
  19. Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program 2011; 2011:273.
  20. Dedeken L, Lê PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol 2014; 165:402.
  21. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361:2309.
  22. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22:1.
  23. Locatelli F, Stefano PD. New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies. Br J Haematol 2004; 125:3.
  24. Eggleston B, Patience M, Edwards S, et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. Br J Haematol 2007; 136:673.
  25. Shenoy S. Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant 2007; 40:813.
  26. Kelly P, Kurtzberg J, Vichinsky E, Lubin B. Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. J Pediatr 1997; 130:695.
  27. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101:2137.
  28. Adamkiewicz TV, Szabolcs P, Haight A, et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant 2007; 11:641.
  29. Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120:4285.
  30. Amado RG, Schiller GJ. Nonmyeloablative approaches to the treatment of sickle hemoglobinopathies. Semin Oncol 2000; 27:82.
  31. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant 2000; 25:131.
  32. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9:519.
  33. Horan JT, Liesveld JL, Fenton P, et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005; 35:171.
  34. Abboud MR. Hematopoietic stem-cell transplantation for adults with sickle cell disease. N Engl J Med 2009; 361:2380.
  35. Baron F, Dresse MF, Beguin Y. Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease. Transfusion 2000; 40:1071.